HGH Fragment 176-191
Available Suppliers & Pricing
Summary
HGH Fragment 176-191 is a C-terminal segment of human growth hormone often discussed alongside modified analogs such as AOD9604/LAT8881. Direct evidence for the unmodified fragment is limited and largely preclinical. Older rodent adipose studies examined nearby C-terminal sequences for antilipogenic, lipolytic, glucose, and insulin effects. Later work with AOD9604, a modified hGH C-terminal analog, reported effects on fat oxidation and lipid metabolism in obese rodents and ex vivo adipose models, with evidence that it does not act through the classical growth hormone receptor in those systems. AOD9604/LAT8881 is not identical to unmodified HGH Fragment 176-191, so its clinical development history cannot be used as direct proof for the fragment.
Potential Benefits
C-Terminal Fragment Research
Direct C-terminal fragment studies in rodents suggest antilipogenic activity in adipose tissue, but results do not establish human fat-loss efficacy [1][2].
Related AOD9604 Context
AOD9604, a modified hGH C-terminal analog, increased fat oxidation and reduced weight gain in obese mouse models, but this is analog- and model-specific [3][4].
Evidence Boundary
Human evidence for the specific unmodified fragment is not adequate for body-fat, metabolic, pain, or performance claims [5].
Safety Information
Human Safety Not Established
Human safety and efficacy are not established for unmodified HGH Fragment 176-191; most supportive data are animal, ex vivo, or from modified analogs [1][3][5].
Metabolic Caution
Early C-terminal hGH fragment research reported glucose and insulin effects with some synthetic fragments, so metabolic neutrality should not be assumed [6].